In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1610-1616

  Rastogi, Nalin ^a   Goh, Khye Seng ^a   Bryskier, Andre ^b,c   Devallois, Anne ^a  

^a Institut Pasteur de Guadeloupe   (Guadeloupe)

^b SANOFI   (France)

^c CENTRE HOSPITALIER VICTOR DUPOUY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; STRAIN DIFFERENCE; TUBERCULOSIS;

EID: 8944226573     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1610     Document Type: Article

References (40)

1. Alangaden, G. J., E. K. Manavathu, S. B. Vakulenko, N. M. Zvonok, and S. A. Lerner. 1995. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob. Agents Chemother. 39:1700-1703.
2. Bazile, S., N. Moreau, D. Bouzard, and M. Essiz. 1992. Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones. Antimicrob. Agents Chemother. 36:2622-2627.
3. Bloch, A. B., G. M. Cauthen, I. M. Onorato, G. Kenneth, G. Dansbury, G. D. Kelly, C. R. Driver, and D. E. Snider. 1994. Nationwide survey of drug-resistant tuberculosis in the United Slates. JAMA 271:665-671.
4. Cavalieri, S. J., J. R. Biehle, and W. E. Sanders, Jr. 1995. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39: 1542-1545.
5. Dhople, A. M., and M. A. Ibanez. 1995. In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae. Antimicrob. Agents Chemother. 39:2116-2119.
6. Frieden, T. R., T. Sterling, A. Pablos-Mendez, J. O. Kilburn, G. M. Gauthen, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med 328:521-526.
7. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barett, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxaein {l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
8. Goodwin, S. D., H. A. Gallis, A. T. Chow, F. A. Wong, S. C. Flor, and J. A. Bartlett. 1994. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 38:799-804.
9. Hayakawa, I., S. Atarashi, S. Yokohama, M. Imamura, K. Sakano, and M. Furukawa. 1986. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob. Agents Chemother. 29:163-164.
10. Heifets, L. B. 1987. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 68:267-276.
11. Immamura, M., S. Shibamura, I. Hayakawa, and Y. Osada. 1987. Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob. Agents Chemother. 31:325-327.
12. Iseman, M. D. 1993. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. 329:784-791.
13. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
14. Ji, B., E. G. Perani, C. Petinom, L. N'Deli, and J. Grosset. 1994. Clinical trial of ofloxacin alone and in combination with dapsone plus clofaziminc for treatment of lepromatous leprosy. Antimicrob. Agents Chemother. 38:662-667.
15. Klemens, S. P., C. A. Sharpe, M. C. Rogge, and M. H. Cynamon. 1994. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 38:1476-1479.
16. Lalande, V., C. Truffot-Pernot, A. Paccaly-Moulin, J. Grosset, and B. Ji. 1993. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 37:407-413.
17. Lee, C. N., and L. B. Heifets. 1987. Determination of minimal inhibitory concentrations of antituberculous drugs by radiometric and conventional methods. Am. Rev. Respir. Dis. 136:349-352.
18. Mor, N., J. Vanderkolk, and L. Heifets. 1994. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob. Agents Chemother. 38:1161-1164.
19. Nakashima, M., T. Uematsu, M. Kanamura, O. Okazaki, S. Hashimoto, and H. Tachizawa. 1988. Pharmacokinetics of DR-3355, a new quinolone, in healthy volunteers, abstr. 951, p. 278. In Program and abstracts of the 28th Interscienee Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Neu, H. C., and N.-X. Chin. 1989. In vitro activity of S-ofloxacin. Antimicrob. Agents Chemother. 33:1105-1107.
21. Pascual, A., I. Garcia, and E. J. Perea. 1990. Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 33:653-656.
22. Pascual, A., I. Garcia, and E. J. Perea. 1990. Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob. Agents Chemother. 34:277-280.
23. Rastogi, N. 1993. Mycobacteria as intracellular pathogens: current notions of pathogenicity, virulence, and drug resistance and their relation to effective therapy, p. 245-300. In D. Raoult (ed.), Antimicrobial agents and intracellular pathogens. CRC Press, Boca Raton, Fla.
24. Rastogi, N., and M. C. Blom-Potar. 1990. Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line. Zentralb. Bakteriol. 273:195-199.
25. Rastogi, N., and K. S. Goh. 1991. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob. Agents Chemother. 35:1933-1936.
26. Rastogi, N., K. S. Goh, and H. L. David. 1989. Drug susceptibility testing in tuberculosis: a comparison of the proportion methods using Lowenstein-Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method. Res. Microbiol. 140:405-417.
27. Rastogi, N., K. S. Goh, P. Ruiz, and M. Casal. 1995. In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 39:1162-1165.
28. Rastogi, N., A. Kochi, B. Vareldzis, K. Styblo, J. T. Crawford, W. R. Jarvis, J. E. McGowan, Jr., C. Perrone, H. L. David, Y. Zhang, D. L. Cohn, and M. D. Iseman. 1993. 9th Forum in Microbiology. Emergence of multiple-drug-resistant tuberculosis: fundamental and applied research aspects, global issues and current strategies. Res. Microbiol. 144:103-158.
29. Rastogi, N., and V. Labrousse. 1991. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob. Agents Chemother. 35:462-470.
30. Rastogi, N., V. Labrousse, and A. Bryskier. 1995. Intracellular activities of roxithromycin used alone and in combination with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob. Agents Chemother. 39:976-978.
31. Rastogi, N., V. Labrousse, K. S. Goh, and J. P. Carvalho de Sousa. 1991. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob. Agents Chemother. 35:2473-2480.
32. Rastogi, N., B. C. Ross, B. Dwyer, K. S. Goh, S. Clavel-Sérès, V. Jeantils, and P. Cruaud. 1993. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 11:901-907.
33. Riley, L. W. 1993. Drug-resistant tuberculosis. Clin. Infect. Dis. 17(Suppl. 2):S442-S446.
34. Saito, H., K. Sato, H. Tomioka, and S. Dekio. 1995. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tubercle Lung Dis. 76:377-380.
35. Siddiqi, S. H., J. E. Hawkins, and A. Laszlo. 1985. Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods. J. Clin. Microbiol. 22:919-923.
36. Siddiqi, S. H., J. P. Libonati, and G. Middlebrook. 1981. Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 13:908-912.
37. Skinner, P. S., S. K. Furney, D. A. Kleinert, and I. A. Orme. 1995. Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:750-753.
38. Tanaka, M., M. Otsuki, T. Une, and T. Nishino. 1990. In vitro and in vivo activity of DR-3355, an optically active isomer of ofloxacin. J. Antimicrob. Chemother. 26:659-666.
39. Tsukamura, M., E. Nakamura, S. Oshii, and H. Amano. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL-8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131:352-356.
40. Une, T., T. Fujimoto, K. Sato, and Y. Osada. 1988. In vitro activity of DR-3355, an optically active ofloxacin. Anlimicrob. Agents Chemother. 32: 1336-1340.